Cancer resistance to therapies against the EGFR-RAS-RAF pathway: The role of MEK
详细信息 查看全文
- 作者：Erika Martinelli<sup> ; sup><sup>erika.martinelli@unina2.itsup><sup> ; sup><sup>erikamartinelli75@yahoo.itsup> ; Floriana Morgillo ; Teresa Troiani ; Fortunato Ciardiello
- 关键词：MEK ; Resistance ; NSCLC ; CRC
- 刊名：Cancer Treatment Reviews
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：53
- 期：Complete
- 页码：61-69
- 全文大小：1742 K
- 卷排序：53
文摘
MEK1/2 is a transducer of RAS-RAF-MAPK signalling cascade with a role in cancers. New drugs targeting MEK1/2 have been developed, particularly for RAS mutant tumours. MEK inhibitors display a modest single agent activity. No other biomarkers than BRAF mutations predict the sensitivity to MEK inhibitors. MEK activation is described in resistance to targeted agents used in CRC and NSCLC.